<DOC>
	<DOC>NCT00518739</DOC>
	<brief_summary>This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II Dose (RP2D), pharmacodynamic, and clinical activity of MK2461.</brief_summary>
	<brief_title>MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients must be at least 18 years of age, with adequate organ function, and an ECOG performance of &lt;2 Patients must be willing to undergo prestudy and post dose tumor biopsy and have tumor accessible to biopsy (waived during Part A) No chemotherapy, radiotherapy, or biological therapy with 4 weeks of study participation Patients must not have primary central nervous system tumor Patient has had prescription or nonprescription drugs or other products known to be metabolized by CYP3A4 that cannot be discontinued prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>